CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry, as a full-service, non-clinical global drug development partner. Its business spans research model technologies, discovery and safety assessment services, and manufacturing support products and services. The company runs three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue reached $4.0 billion, with DSA contributing 59.8%, RMS 21.1%, and Manufacturing 19.1%. CRL currently operates across more than 120 sites in over 20 countries.

From a competitive-moat perspective, the integrated portfolio—covering target identification through non-clinical development and product release—creates a one-stop scientific-partner positioning. However, the current profitability metrics do not confirm that this moat is generating strong shareholder returns right now. The company reports a net margin of -6.0% and return on equity of -7.7%, and its P/E ratio stands at -69.9. Those figures indicate that scale and service breadth exist, but they are not translating into positive bottom-line performance at this snapshot. For investors, the analytical question is whether operational restructuring can close the gap between strategic positioning and reported margins.

Financial posture

CRL carries a market capitalization of $16.3 billion as of the current snapshot. The valuation multiple is negative: a P/E of -69.9, which directly reflects that trailing earnings are negative. With a net margin of -6.0% and ROE of -7.7%, the company is currently consuming capital rather than compounding it. That combination means the stock is being priced on expectations of a turnaround or on the strategic value of its platform, not on current profitability.

The stock's beta of 1.40 signals materially higher volatility than the overall market—roughly 40% more price sensitivity to broad market moves. At a price of $338.54, CRL is trading well above its 50-day exponential moving average of $305.40, and the RSI is 56.2, which is near neutral-to-moderate momentum territory. None of these figures imply a directional call, but they do frame the stock as a higher-volatility, current-loss enterprise whose market value depends on execution of its strategic plan rather than on trailing earnings yield.

Strategic priorities & outlook

The company's most recent 10-K filing outlines a near-term agenda built around footprint optimization, organizational integration, and biologics expansion. Charles River plans to close or consolidate approximately 12 additional sites over the next two years, with the majority of those actions falling within the DSA and RMS segments. That footprint rationalization is aimed at aligning physical capacity with demand and reducing cost complexity.

Operationally, CRL intends to integrate Discovery Services and Safety Assessment into one overarching DSA organization, supported by a combined sales force and unified leadership approach. The stated objective is to become the scientific partner of choice by delivering a comprehensive and integrated portfolio that accelerates biomedical research and therapeutic innovation. Separately, the company is pursuing expansion of Biologics Testing Solutions service offerings and facilities in the U.S. and Europe.

A recent move aligned with supply security came in January 2026, when CRL acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates. The filing notes this acquisition supports DSA supply operations and RMS third-party sales, tying directly into the need for reliable research-model supply chains.

Macro & geopolitical exposure

As a Healthcare / Medical - Diagnostics & Research company, CRL sits at the intersection of pharmaceutical R&D spending, regulatory oversight, and global supply chains. Its exposure includes FDA and international regulator changes affecting non-clinical testing standards, animal-welfare regulation (particularly relevant given its reliance on non-human primates and other research models), and shifts in government and private biomedical research funding.

The global footprint across more than 20 countries introduces currency translation risk and trade-policy sensitivity, especially for the movement of research models, biological samples, and testing equipment. The business is also exposed to the cyclicality of biotech funding: when capital becomes more expensive or venture flows slow, early-stage drug development demand can soften. Commodity and logistics costs for animal husbandry, transportation, and facility operations add another layer of macro sensitivity.

Recent developments

The news flow ahead of the scheduled November 4, 2026 earnings release has been earnings-focused and operational. On November 2, 2026, zacks.com published "Charles River's Q3 Earnings on Deck: What's in Store for the Stock?" Two days earlier, on October 28, 2026, zacks.com also ran "Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?" That same day, Ariel Appreciation Fund's Q3 2026 scorecard coverage on seekingalpha.com included CRL among its reported buys, sells, and standouts. On October 27, 2026, businesswire.com reported that "Charles River Leverages Virtual Control Groups in GLP Studies," highlighting an operational innovation in good laboratory practice safety studies.

Collectively, these items underscore two themes: market attention is concentrated on the upcoming Q3 2026 report, and the company is continuing to introduce new scientific capabilities—such as virtual control groups—that could influence study efficiency and regulatory acceptance over time.

Earnings behavior & post-earnings drift

CRL's recent earnings history shows a consistent beat pattern. Over the last eight reported quarters, the company has beaten estimates in all eight instances, for a 100% beat rate, with an average earnings surprise of 9.3%. The average 5-day price move in the five trading days after those reports has been 1.24%, classified as an upward post-earnings drift.

The most recent four quarters illustrate that an earnings beat does not always translate into an immediate positive price reaction. For the August 5, 2026 report, actual EPS came in at $3.02 against an estimate of $2.74—a 10.2% surprise—and the stock rose 1.84% the next day and 9.07% over the following five sessions. By contrast, the May 7, 2026 report delivered actual EPS of $2.06 versus $1.96 (a 5.1% beat), yet the stock fell 2.23% the next day and dropped 12.42% over the next five trading days. The February 18, 2026 quarter produced a $2.39 actual EPS versus $2.33 estimate (2.6% surprise), with the stock up 3.95% the next day and 6.05% over five days. The November 5, 2025 report showed actual EPS of $2.43 versus $2.32 (4.7% surprise), leading to a 1.9% next-day gain and 2.27% five-day gain.

Looking ahead, CRL is scheduled to report next on November 4, 2026, before the market open, with a consensus EPS estimate of $2.97. The historical data suggest the company has a strong record of exceeding the official estimate, but the market's real expectation may be higher than the published consensus, and the price reaction has varied materially even when results beat.